https://assets.capyfin.com/instruments/678fdc13234e27009c5d5fd6.png avatar
Maravai
🇺🇸 NASDAQ:MRVI
View Company
OverviewEarningsDividends
•
Sep 30, 2024

Maravai Q3 2024 Earnings Report

Reported third quarter results with revenue of $65.2 million and announced agreement to acquire the DNA and RNA business of Officinae Bio.

Key Takeaways

Maravai LifeSciences reported a 2.5% decrease in revenue for the third quarter, totaling $65.2 million. The company experienced a net loss of $(176.0) million, which included a goodwill impairment of $154.2 million. They updated their full-year revenue guidance for 2024 to a range of $255.0 million to $265.0 million.

Quarterly revenue reached $65.2 million.

Net loss was $(176.0) million, including a goodwill impairment of $154.2 million.

Adjusted EBITDA was $12.7 million.

Full year 2024 revenue guidance updated to $255.0 million to $265.0 million.

Total Revenue
$65.2M
Previous year: $66.9M
-2.5%
EPS
-$0.02
Previous year: -$0.01
+100.0%
Adjusted EBITDA
$12.7M
Gross Profit
$28.4M
Previous year: $29.5M
-3.7%
Cash and Equivalents
$578M
Previous year: $580M
-0.2%
Free Cash Flow
$4.55M
Previous year: -$1.66M
-373.6%
Total Assets
$1.28B
Previous year: $2.27B
-43.6%

Maravai

Maravai

Maravai Revenue by Segment

Forward Guidance

Revenue expectations for 2024 are now expected to be in the range of $255.0 million to $265.0 million. Adjusted EBITDA (non-GAAP) margins are now expected to be in the range of 16% to 18%.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Maravai